Professor Len Harrison wins JDRF Australia Lifetime Achievement Award

December 11, 2013

Diabetes researcher Professor Len Harrison has been awarded the 2013 JDRF Australia Lifetime Research Achievement Award for his research to improve treatments for people with diabetes, or prevent its development.

The JDRF Australia Lifetime Research Achievement Award recognises the long-standing nature and high quality of contributions of the very best Australian researchers who have steered global directions of type 1 diabetes research.

Professor Harrison, who is a researcher at the Walter and Eliza Hall Institute and clinician at The Royal Melbourne Hospital, was presented with the award last night at the International Congress of the Immunology of Diabetes Society in Lorne, Victoria, Australia. Professor Harrison said he felt very privileged to be recognised in this way.

"As we know type 1 diabetes is increasing in Australia, and I'm grateful for community support, and the support of the JDRF, to continue to find new and better treatments for people with diabetes, and develop ways of preventing or delaying the onset of diabetes," he said. "Medical research is a team effort and I would like to acknowledge everyone involved in the research that has earned this generous award."

Head of JDRF Australia's Research Development Dr Dorota Pawlak said Professor Harrison's leadership and guidance has played a vital role in recognising Australia as a major global hub for type 1 diabetes research.

"Professor Harrison's career has spanned exceptional achievements in understanding the mechanisms of immune tolerance, advancing antigen specific therapies and defining paradigms for factors that contribute towards the development of type 1 diabetes," Dr Pawlak said.

"His lifelong work to understand autoimmunity in type 1 diabetes and pioneering work in the prevention of the disease has significantly accelerated research progress towards JDRF's mission to cure type 1 diabetes and its complications. It has provided great hope for better therapies and treatments for people living with type 1 diabetes every day."

Professor Harrison's major research interests are immune regulation and immune therapies, applied to type 1 diabetes. His achievements are documented in 500 clinical and basic research publications and several patents. His awards for research include C.J. Martin Fellowship, Wellcome Australia (Glaxo) Medal, Susman Prize (Royal Australian College of Physicians), Kellion Medal (Australian Diabetes Society) and Rumbough Award for Scientific Excellence (JDRF).
-end-


Walter and Eliza Hall Institute

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.